Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Colleoni M, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber R, Coates A, Di Leo A, Regan M, Goldhirsch A, O'Reilly S, Müller B, Marth C, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas M, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2017; 19:127-138.
Nov 17, 2017
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
Nov 17, 2017
Lancet Oncol 2017; 19:127-138
Colleoni Marco, Di Lauro Vincenzo, Gombos Andrea, Ruhstaller Thomas, Burstein Harold, Ribi Karin, Bernhard Jürg, Viale Giuseppe, Maibach Rudolf, Rabaglio-Poretti Manuela, Gelber Richard D, Coates Alan S, Di Leo Angelo, Regan Meredith M, Goldhirsch Aron, O'Reilly Seamus, Müller Bettina, Marth Christian, Luo Weixiu, Karlsson Per, Chirgwin Jacquie, Aebi Stefan, Jerusalem Guy, Neven Patrick, Hitre Erika, Graas Marie-Pascale, Simoncini Edda, Kamby Claus, Thompson Alastair, Loibl Sibylle, Gavilá Joaquín, Kuroi Katsumasa, SOLE Investigators
more
